American Heart Journal
Volume 154, Issue 1 , Pages 62-70, July 2007

Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty—Influence on myocardial reperfusion, left ventricular performance, and clinical events

1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

Received 1 October 2006; accepted 15 March 2007. published online 28 April 2007.

Background

Platelet reactivity is believed to play a key role in the pathophysiology of ST-segment elevation myocardial infarction (STEMI). We sought to determine whether platelet reactivity predicts impaired myocardial reperfusion, left ventricular (LV) dysfunction, and clinical events in an unselected group of patients with STEMI.

Methods

Platelet reactivity was measured before primary angioplasty in 125 consecutive patients with the use of Platelet Function Analyzer-100. Six-month follow-up was performed.

Results

Patients were stratified into 4 quartiles according to the collagen adenosine diphosphate closure time (CADP-CT), with the fourth quartile (CADP-CT ≤55 seconds; n = 32) defined as high reactivity. There was an increasing rate of diabetes across quartiles: 6% in the first and 38% in fourth (P < .0001). Myocardial Blush Grade 0 or 1 and the absence of ST-segment resolution (≤50%) were observed more often in the fourth quartile than in quartiles 1 through 3 (84% vs 22%, 27%, 35% and 81% vs 16%, 17%, 26%, respectively; P < .0001 for all). In logistic regression, high reactivity was an independent predictor of Myocardial Blush Grade 0 or 1 (odds ratio [OR], 22.7; 95% confidence interval [CI], 6.5-78.8; P < .0001), ST-segment resolution ≤50% (OR, 28.6; 95% CI, 8.6-95.2; P < .0001), LV remodeling (OR, 10.4; 95% CI, 3.3-32.7; P < .0001), lack of early (OR, 7.9; 95% CI, 2.8-22.3; P < .0001) and late LV functional recovery (OR, 7.3; 95% CI, 2.9-18.8; P < .0001), and clinical events (OR, 7.8; 95% CI, 2.5-24.9; P = .0005).

Conclusions

Platelet reactivity is an independent predictor of myocardial reperfusion. Moreover, CADP-CT being a marker of myocardial reflow may also provide early prognostic information concerning LV performance and adverse clinical events after STEMI.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the Polish State Committee for Scientific Research (KBN 2 P05C 045 26 and KBN 3 P05B 122 23).

PII: S0002-8703(07)00243-8

doi:10.1016/j.ahj.2007.03.021

American Heart Journal
Volume 154, Issue 1 , Pages 62-70, July 2007